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Abstract
Introduction We have previously shown that FTI-277, a farnesyl
transferase inhibitor (FTI), enhances the efficacy of tamoxifen
(Tam) in inhibiting the proliferation of the estrogen dependent
MCF-7 cell line. As the cellular response to Tam is the result of
an inhibition of both estrogen receptor-dependent and -
independent pathways, we have used the estrogen receptor
selective anti-estrogen ICI182,780 and N-pyrrolidine(-
phenylmethyl-phenoxy)-ethanamine-HCl (PBPE), a selective
ligand of anti-estrogen binding site (AEBS), to dissect out the
mechanism(s) associated with the observed additivity resulting
from combination treatment with FTI-277 and Tam. Moreover,
for these studies, FTI-277 has been replaced by R115,777, a
FTI currently in phase III clinical trials.
Methods The quantitative sulphorhodamine B (SRB)
colorimetric assay was used to determine the growth inhibitory
effect of agents on MCF-7 cells. Dose response interactions
between R115,777-Tam, R115,777-ICI182,780 and
R115,777-PBPE were evaluated, at the IC50 point, using the
isobologram method. Apoptotic cell death (DNA fragmentation,
nucleus condensation and cytokeratin 18 cleavage) and
inhibition of the mevalonate pathway (western blot) were also
determined.
Results Combinations of the specific FTI R115,777 with either
ICI182,780 or PBPE exhibit a synergistic effect on MCF-7 cell
growth inhibition, while its combination with Tam is additive, as
previously reported for FTI-277. Apoptosis is detected after
treatment with combinations of R115,777 with either Tam or
PBPE but not with ICI182,780, suggesting that each
combination inhibits cell proliferation by different mechanisms.
Even though the ER pathway has not yet been deciphered, it is
shown here that the AEBS pathway is able to interfere with the
mevalonate pathway at the level of protein farnesylation.
Conclusion Overall, this work reveals that combinations of
R115,777 with either selective ER ligands or a selective AEBS
ligand are able to induce large increases in their anti-proliferative
activities on MCF-7 cells. Moreover, these results suggest that
it may be of definite interest to evaluate combinations of
R115,777 with different anti-estrogens in the treatment of ER
positive breast tumours. Based on these experimental data,
such combinations may prove beneficial in different clinical
scenarios or when used in specific sequences; studying the
combination of R115,777 with ICI182,780 for early treatment
and reserving combinations with either Tam or a selective AEBS
ligand, such as BMS-217380-01, for more resistant disease.
Introduction
Tamoxifen (Tam) remains the most frequently prescribed agent
for the treatment of hormone responsive breast cancer. Effi-
cacy for Tam has been demonstrated in the treatment of all
stages of breast cancer and it is also used as prevention ther-
apy for women at high risk of developing breast cancer.
Although Tam is effective initially in many patients, a major
obstacle to its long-term use is tumour resistance. To resolve
this problem, we decided to evaluate the effects of combining
Tam with a farnesyl transferase inhibitor (FTI). Although the
role of combination therapy versus sequential therapies with
single agents remains controversial in the treatment of breastR1159
AEBS = anti-estrogen binding site; ER = estrogen receptor; FTI = farnesyl transferase inhibitor; PBPE = N-pyrrolidine(-phenylmethyl-phenoxy)-ethan-
amine-HCl; PBS = phosphate-buffered saline; SRB = sulphorhodamine B; Tam = tamoxifen.
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drugs with differing mechanisms of action have generally
proved more effective than single-drug therapies. In this basis,
combinations of FTIs with a variety of commonly used antican-
cer agents have been tested on human tumours [1]. The FTI
R115,777 represents one of the first-in-class inhibitors to
enter the clinic [2]. Clinical trials have shown that this com-
pound has an acceptable safety profile, allowing the adminis-
tration of biologically active doses. Phase II clinical trials in
patients with metastatic breast carcinoma have shown that
R115,777 has reproducible single-agent activity [3]. In this
present study, the activity of combined treatment with Tam and
R115,777 was investigated using a mammary cancer cell line
(MCF-7), and the results are compared with those from our
previous studies using FTI-277 (an experimental FTI not in clin-
ical usage) to evaluate the potential value of this combined
therapy in the treatment of advanced breast cancer.
The antitumour effect of Tam is believed to be due to a combi-
nation of hormone receptor dependent (estrogen receptor
(ER)-mediated with two receptor subtypes, ERα and ERβ) and
independent (non-ER-mediated) mechanisms [4]. The signal-
ling proteins in the non-ER-mediated pathways [5] include
interactions with microsomal anti-estrogen-binding sites
(AEBS) that are high affinity binding sites for Tam [6,7]. AEBS
are different from ERs because they have no affinity for 17β-
estradiol or steroidal anti-estrogens, and we recently reported
that these sites consist of several proteins involved in choles-
terol metabolism [8]. Previous reports have suggested that
Tam inhibits MCF-7 cell proliferation [9] by binding to both
ERs and AEBS [7,10] and can induce apoptotic cell death,
both in vitro [11] and in vivo [12].
In parallel, FTIs inhibit the growth of a broad variety of human
tumour cells in vitro and studies to date have not identified any
cellular characteristics that predict the antitumour efficacy of
this class of agent. In vitro, however, FTI treatment of tumour
cells has been associated with activation of apoptotic path-
ways [13].
We have previously shown the involvement of pocket proteins
[14] and genomic ER effects [15] in the additive efficacy of a
combination of Tam and FTI277. To dissect out that portion of
the Tam effect associated with the 'AEBS pathway', we com-
pare here the effects of combining R115,777 with a selective
AEBS ligand (N-pyrrolidine(-phenylmethyl-phenoxy)-ethan-
amine-HCl (PBPE)) [10] or with a selective estrogen receptor
ligand (ICI182,780) on MCF-7 cell proliferation. The effects of
such treatments on the induction of cellular apoptosis have
been evaluated by monitoring cell cycle alterations and cas-
pase involvement. The contribution of ERs to apoptosis induc-
tion has also been determined by comparing the effects of
combined treatments with either the pure anti-estrogen
ICI182,780 or the AEBS selective ligand PBPE.
Materials and methods
Cell lines
The human adenocarcinoma breast cell line MCF-7 was
obtained from the American Tissue Culture Collection (Manas-
sas, VA, USA). MCF-7 cells were grown routinely in RPMI
1640 medium supplemented with 5% fetal bovine serum
(Gibco BRL, Life Technologies, Cergy Pontoise, France) and
2 mM L-glutamine. The cells were incubated at 37°C in a
humidified 5% CO2 incubator.
For all experiments, the cells were treated with R115,777
(Janssen Research Foundation, Janssen Pharmaceutica, L.P.,
Titusville, NJ 08560, USA), Tam (Sigma-Aldrich S.a.r.l. St
Quentin Fallavier, France), ICI182,780 (Tocris Bioscience,
Ellisville, Missouri 63021 USA), PBPE (synthesized in our lab-
oratory) [16] or vehicle, and the medium was changed every 2
days. R115,777, Tam, ICI182,780 and PBPE were all dis-
solved in ethanol and then diluted 103-fold directly into the cul-
ture medium.
Sulphorhodamine B assay for proliferation
The quantitative sulphorhodamine B (SRB) colorimetric assay
[17] was used to determine the growth inhibitory effect of
drugs on MCF-7 cells. Cells were seeded at 3,500 per well in
96-well plates and grown for 24 h. The cells were then treated
with increasing concentrations of compounds and grown for a
further 5 days. The medium was changed after 2 days. At the
end of the incubation, cells were fixed with 50% trichloracetic
acid (1 h at 4°C), stained for 30 minutes at room temperature
with 50 µl of a 0.4% w/v SRB solution (Sigma) in 1% acetic
acid. SRB was then removed and cells were quickly rinsed
four times with 1% acetic acid. After air-drying, protein-bound
dye was dissolved in 150 µl of 10 mM unbuffered Tris base
(pH 10.5) for 5 minutes on a gyratory shaker. The pink SRB
was quantified by measuring the optical density at 540 nm. For
each condition, average cell density and the standard devia-
tion were calculated from the data of six wells.
Isobologram analysis
Dose response interactions between the following combina-
tions: R115,777-Tam, R115,777-ICI182,780, R115,777-
PBPE at the IC50 (inhibitory concentration 50%) point were
evaluated by the isobologram method of Steel and Peckham
[18]. When the data points of the drug combination fall within
the area surrounded by two lines (envelope of additivity), the
combination is regarded as additive. When the data points of
the drug combination fall to the left of the envelope (i.e., the
combined effect is caused by lower doses of the two agents
than predicted), the combination is regarded as having a
supra-additive effect (synergism). Finally, when the data points
fall to the right of the envelope, the combination is regarded as
having a protective effect.
To determine the envelope of additivity, the two dose-
response curves of R115,777 with either Tam, ICI182,780, or
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tions. Based on these data, two isoeffect curves were con-
structed for each association. In all cases, an incremental
effect was produced by R115,777 for any selected dose of
Tam, ICI182,780, or PBPE.
Mode I line
The addition was calculated by taking the increment in dose
starting from 0 that produced a log cell density that summated
to the IC50 (hetero-addition where there would be no influence
of drug treatment on R115,777 action). If the agents are act-
ing additively through independent mechanisms, the com-
bined data points would lie near this mode I line.
Mode II line
The addition was calculated by taking the increment in dose
starting from the point on the dose-response curve of Tam,
ICI182,780 or PBPE that produces a log cell density that sum-
mated to the IC50 (iso-addition where drug treatment would
modify the basal state of the cells before R115,777 action). If
the agents are acting additively through a similar mechanism,
the combined data points would lie near this mode II line.
Cell cycle analysis
For each condition, 1.5 × 105 cells were seeded into 60 mm
diameter dishes and treated as described above. Following
treatment, cells were collected by trypsinization, washed twice
and resuspended in 500 µl ice cold PBS. The cells were then
fixed in 1.5 ml ice cold absolute ethanol for 30 minutes at 4°C,
washed twice in PBS and stained with propidium iodide (100
µg/ml RNase A in PBS, 0.25% Tween 20 and 50 µg/ml pro-
pidium iodide) for 1 h at 37°C. DNA content was determined
by flow cytometry on a FACS Calibur (Beckton Dickinson and
Co., Meglan, France). Data were collected from 10,000 cells.
The percentage of apoptotic cells was calculated by dividing
the number of cells displaying red fluorescence lower than the
G0–G1 diploid peak by the total number of cells collected
times 100.
DAPI staining
Cells were grown on glass coverslips in 60 mm Petri dishes,
washed once with PBS, fixed in PBS/3.7% formaldehyde for
15 minutes and washed twice with PBS. The coverslips were
then mounted on glass slides with Vectashield mounting
medium with 4'-6-diamidino-2-phenylindole (DAPI; AbCys
75010 Paris, France). In each experiment, a minimum of 200
nuclei were quantified using the ImageQuant software (Molec-
ular Dynamics Inc., Sunnyvale, CA, USA).
Detection of caspase cleavage by flow cytometry
Floating and adherent cells were combined and fixed in meth-
anol at -20°C. After 30 minutes, the cells were washed twice
with PBS containing 0.1% Tween 20. Non-specific binding
was blocked with PBS containing 1% bovine serum albumin
and 0.1% Tween 20 at room temperature. After 10 minutes,
the blocking buffer was removed and the cells were incubated
in 100 µl M30 CytoDeath antibody (1:100; Boehringer Ingel-
heim, France) at room temperature for 60 minutes. To visualize
M30 CytoDeath antibody, a FITC conjugated second antibody
was used (Boehringer) and the FITC signal was evaluated by
flow cytometry. The results are expressed as an index of spe-
cific fluorescence (median fluorescence intensity - median flu-
orescence intensity of untreated cells/median fluorescence
intensity of untreated cells × 100).
Detection of caspase cleavage by immunocytochemistry
Floating and adherent cells are represented in cytospin prep-
arations. Cells were fixed in absolute ethanol/acetic acid
(99:1) for 1 minute. The staining was performed by a Tech-
mate Horizon™ slide processor using a two-step peroxidase-
conjugated polymer backbone visualisation system (EnVi-
sion™, DAKO, Glostrup, Denmark) according to the manufac-
turer's protocol. The chromogenic substrate was DAB (3,3'-
diaminobenzidine). The primary antibody used was the M30
CytoDeath antibody (Boehringer). Negative controls were per-
formed by omission of the primary antibody. All determinations
were performed with at least 400 cells being quantified with
the ImageQuant software for each experimental condition.
Western-blot analyses
At the completion of the experiments, MCF-7 cell monolayers
were washed with ice-cold PBS (Biowittaker Walkersville,
MD, USA) and were then scraped into 100 µl of ice-cold lysis
buffer: 50 mM HEPES, pH 7.5, 150 mM NaCl, 10% (v/v) glyc-
erol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, 1 mM
dithiothreitol and protease cocktail inhibitor (Sigma). The
lysates were then placed on ice, vortexed vigorously at inter-
vals over 10 minutes, centrifuged at 15,000 g for 10 minutes
at 4°C and the supernatants stored at -80°C.
Equal amounts of total protein (5 µg) were submitted to
12.5% SDS-PAGE and then transferred to PVDF membranes.
Proteins were visualized using the ECL+ detection system
(Amersham Biosciences Europe GmbH,(Succursale France,
F-91898 Orsay Cedex, France)) after incubation (overnight at
4°C for primary and 1 h at room temperature for secondary
antibodies) using the primary antibody HDJ2 from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA) and the secondary
antibody anti-mouse horseradish peroxidase.
Protein abundance was quantified by analysis of autoradio-
graphs. Relative band intensities were quantified by densito-
metric analysis (Molecular Dynamics, Sunnyvale, CA, USA).
Quantification of protein levels by this method was linear over
the range of protein concentrations analysed and exposure
times employed in these studies.
Cellular levels of [3H]tamoxifen
Cells were seeded at 180,000 per dish in 60 mm dishes and
incubated with Tam and/or R115,777 as described above in
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lowing such treatment, the cells were washed with PBS, col-
lected by trypsinisation and counted for radioactivity in ready
Emulsifer-safe scintillant (PerkinElmer Boston, MA 02118,
USA).
Results and discussion
Effects of R115,777 when combined with different anti-
estrogens on MCF-7 cell proliferation
We assessed the ability of R115,777 alone and in combina-
tion with anti-estrogens to inhibit the proliferation of MCF-7
cells. Cells were incubated for 5 days with incrementally
increasing concentrations of R115,777 together with either
Tam, ICI182,780 (pure anti-estrogen) or PBPE (selective
AEBS ligand). For each compound, we first plotted individual
dose response curves from which the following IC50 values
were derived: 5.9 nM (R115,777), 4.4 µM (Tam), 0.52 nM
(ICI182,780) and 8.8 µM (PBPE). Analyses of cell prolifera-
tion curves (Fig. 1a–c) showed strong inhibitory effects at low
concentrations of R115,777 when associated with each of the
three anti-estrogens and there was a suggestion of synergy for
each of the combined pairs. To construct isobolograms
according to the method described by Steel and Peckham
[18] we carried out another set of experiments using combina-
tions of the two drugs at concentrations resulting in 50% cell
growth inhibition. Additive effects close to synergistic were
observed between Tam and R115,777 (Fig. 1a, insert), con-
firming our earlier results using another FTI (FTI-277) from a
different chemical class in association with Tam [14]. Although
it can be argued that there is only a tenuous difference
between additivity and synergy for this combination of an FTI
with Tam, and it is accepted that this type of analysis is not
really precise enough to definitively establish additivity
between two agents, the methodology does identify clear
additivity with two different FTIs with diverse molecular struc-
tures. To extend this observation to the evaluation of other anti-
estrogens further, isobolograms were constructed. Isobolo-
gram analyses (Fig. 1b,c, inserts) revealed a synergistic inhibi-
tion of MCF-7 growth with combinations of R115,777 with
both ICI182,780 or PBPE. Because the main high affinity tar-
gets of Tam are ERs and AEBS [5,6,8,19,20] and because of
the synergistic effects between R115,777 and the ER ligand,
results in agreement with data from Ellis et al. [21], together
with the additive or synergistic effects observed with Tam, we
had expected a negative effect with the combination that
includes the selective AEBS ligand. Surprisingly though (Fig.
1c), PBPE also synergizes with R115,777, suggesting that
cross-talk between FTIs and Tam is likely to occur via at least
two different pathways.
To determine at what level this cross-talk occurs, we analysed
the combined effects of R115,777 and Tam on various mark-
ers of cellular apoptosis. The rationale for this study was pro-
vided by an earlier publication by Ellis et al. [21] who proposed
that hydroxy-tamoxifen and ICI182,780 (two selective ligands)
Figure 1
Effects of combining anti-estrogens and R115,777 on the inhibition of MCF-7 cell proliferatio
MCF-7 cell proliferation. Studies were performed using 1.5 × 105 cells 
in 60 mm dishes incubated for 5 days with increasing concentrations of 
(a) R115,777 and tamoxifen, (b) R115,777 and ICI182,780, or (c) 
R115,777 and PBPE. Dose response interactions between these anti-
estrogens and R115,777 were evaluated using the isobologram 
method. The isoeffect curves were constructed, at the IC50 point, 
according to the Materials and methods [18]. X symbolizes the data 
point obtained with a combination of the two agents giving 50% inhibi-
tion. (a) When X falls within the envelope of additivity, the combination 
is considered as having an additive effect. (b,c) When X falls to the left 
of the envelope the combination is considered as having a supra-addi-
tive effect (synergism). PBPE, N-pyrrolidine(-phenylmethyl-phenoxy)-
ethanamine-HCl.
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totic cell death in ER positive breast tumour lines.
R115,777 enhances the apoptotic effect of tamoxifen
We examined the effects of a combination of Tam and
R115,777 on the DNA content of MCF-7 cells using flow
cytometry of propidium iodide-stained cells (Fig. 2). The com-
pounds were added for 5 days either individually or in combi-
nation and in both cases the appropriate carrier was added as
a control. The appearance of a significant fraction of cells with
a DNA content less than 2 N would be indicative of apoptotic
cells. Such a cell population was not detected among
untreated MCF-7 cells. Using these cells we confirmed that
Tam treatment induced an increase of sub-G1 DNA content at
1 and 5 µM (Fig. 2, lanes 2, 5, 8 and 11). We also showed that
cells incubated with high concentrations of R115,777 (25 or
50 nM) showed an increase of the sub-G1 DNA content
equivalent to that obtained with Tam 1 µM. Interestingly, the
combination of R115,777 and Tam produced a large increase
in the sub-G1 population: 35 ± 5% in the presence of both
agents (Fig. 2, lane 13) compared to only 9 ± 3% (Fig. 2, lane
12) or 14 ± 4% (Fig. 2, lane 11) with each agent alone. Cell
death was assayed by two other methods to confirm that
death detected by flow cytometry of propidium iodide-stained
cells was related to apoptosis. First, we used DAPI staining,
which determines nuclear morphology (Fig. 3A, left) and
counted normal and condensed nuclei (Fig. 3A, right). The
number of condensed and fragmented nuclei increased with 5
µM Tam (3.5 ± 0.1%, Fig 3A right lane 2) or with R115,777
(up to 5.9 ± 0.3%, Fig 3A right lanes 3–6) treatment, com-
pared to untreated cells. Once again, the association of Tam
(5 µM) with R115,777 (from 5 to 25 nM) significantly
enhanced the number of cells with condensed nuclei (13.1 ±
0.6 to 22 ± 1%, Fig 3A right lanes 7–9).
Apoptosis was further assessed using the monoclonal anti-
body M30 CytoDeath (M30), which is specific for the neo-
epitope in cytokeratin 18 that becomes available after an early
caspase cleavage during apoptosis. The specific caspase
cleavage site within cytokeratin 18 was assessed either
immuncytochemically (Fig. 3B) or was analysed by flow cyto-
moetry (Fig. 3C). We used M30 CytoDeath to selectively stain
apoptotic cells, and M30 positive cells were scored (Fig. 3B).
Of the cells treated by Tam alone, 19.6% were positive (Fig.
3B, lane 2). This result confirmed that Tam induced cleavage
of the specific caspase cleavage site within cytokeratin 18 in
breast cancer cells [11,22]. R115,777 treatment induced
4.1% to 8.4% M30 positive cells (Fig 3B, lanes 3–6), as pre-
viously reported for other FTIs with mammalian cells [23].
Once again, the combined effects of R115,777 and Tam were
higher (up to 40.4%, Fig 3B, lanes 7–10) than that expected
from the sum of the individual effects. Flow cytometry analysis
confirmed the immunocytochemical counts. R115,777 plus
Tam significantly increased the M30-positive cell population
(up to 74.2%; Fig. 3C, lanes 7–10). The M30-positive cell
population was much smaller following treatment with either
R115,777 (10.4% to 22.1%; Fig. 3C, lanes 3–6) or Tam
(22.5%; Fig. 3C, lane 2) alone. These results were obtained in
three independent experiments with little intra-assay varia-
tions; however, the difficulty of cell counting (from 200 to 400
cells per assay) has prevented our carrying out the extensive
series of experiments required for isobologram constructions.
Overall, these data show that R115,777, which induces neg-
ligible apoptosis by itself, when combined with Tam results in
significant apoptosis induction in MCF-7 cells. To differentiate
between the involvement of the ER and AEBS pathways in this
Tam effect, we compared the apoptosis-inducing activities of
ER or AEBS selective ligands
Effects of R115,777 and different anti-estrogens on 
caspase cleavage
To define any possible involvement of the ER or AEBS path-
ways in apoptosis induction, a set of experiments similar to
those described in Fig. 3c were performed using R115,777 in
association with three different 'anti-estrogens', Tam,
ICI182,780 or PBPE. Flow cytometric analyses were per-
formed following M30 staining of MCF-7 cells treated for 5
days with these three different combinations of agents. As
shown in Fig. 4, 10 µM PBPE was able to increase the number
of M30 positive cells (lane 12) to the same extent as 5 µM Tam
(lane 4). In contrast, 5 nM ICI182,780 treatment resulted in
only modest cytokeratin 18 cleavage (Fig. 4, lane 8). The com-
bination of R115,777 with ICI182,780 resulted in slightly
increased M30 staining (Fig. 4, lanes 9–11) compared with
R115,777 treatment alone (Fig. 4, lanes 1–3), suggesting that
ER is only minimally involved in the synergistic induction of
Figure 2
DNA fragmentation was determined using flow cytometric analysis. 
MCF-7 cells were incubated for 5 days with tamoxifen (Tx) and 
R115,777. Floating and adherent cells were harvested, fixed and their 
DNA was stained using propidium iodide. Data are shown as the per-
centage of cells with a sub-G1 DNA content over the total number of 
cells. Each point is the mean value from 6 × 104 cells, and data are 
expressed as the mean of three independent experiments. Error bars 
indicate the standard error of the mean.
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R115,777 and Tam.
A similar experiment revealed that the combination of
R115,777 with Tam was as efficient in inducing M30 staining
(Fig. 4, lanes 5–7) as was R115,777 plus PBPE (Fig. 4, lanes
13–15), suggesting that the major part of the apoptosis induc-
ing effect of Tam either alone or in association with R115,777
is under the control of the AEBS pathway.
These data, therefore, would be consistent with the proposal
that the first level of 'cross talk' between the two agents would
be that one increases the intracellular concentration of the
other, while the second level would be that one binds to the
Figure 3
Nuclear condensation of cells incubated for 5 days with tamoxifen (Tx) and R115,777. (a) Cells were fixed and stained with the DNA intercalating 
agent DAPI (left) and nuclei were examined by fluorescence microscopy. DAPI-stained nuclei were counted as normal or condensed nuclei (right). 
One randomly selected field is presented for each treatment. For three independent experiments, quantification of at least 200 nuclei was performed 
for each treatment. Error bars indicate the mean values ± standard error of the mean. (b) Cells were fixed and stained for the detection of the cas-
pase cleavage product of cytokeratin 18 by immuno-histochemistry. Floating and adherent cells are represented in cytospin preparations. These 
preparations were fixed and stained with monoclonal antibody M30 CytoDeath. The proportion of positive cells (brown) was calculated as a percent-
age of the total number of cells. All determinations were performed in triplicate with at least 400 cells being counted. Error bars indicate the mean 
values ± standard error of the mean. (c) Cells were fixed and stained for the detection of the caspase cleavage product of cytokeratin 18 by FACS. 
Floating and adherent cells were harvested, fixed and stained with the fluoresein-conjugated monoclonal antibody M30 CytoDeath and analysed 
using flow cytometry. The proportion of positive cells was calculated as a percentage of the total number of cells. Data are representative of one to 
three independent experiments; intra-assay variations were <1%.
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bindings assays and verified that R115,777, like FTI 277, does
not interact either with ERs or with AEBS (data not shown).
R115,777 does not affect the cellular uptake of 
[3H]tamoxifen
We next examined whether R115,777 was able to increase
the cellular uptake of Tam. Exposure to increasing concentra-
tions of R115,777 (from 2 to 50 nM) did not modify the cellular
level of tritiated Tam in MCF-7 cells (data not shown). Thus,
the effects of combining R115,777 with Tam were not attrib-
utable to any increase of cellular Tam concentrations by the
FTI.
With the unavailability of an assay for R115,777 or a radiola-
belled product we were unable to determine the effects of Tam
addition on the intracellular concentration of R115,777. To cir-
cumvent this problem, we looked for any farnesylation inhibi-
tory activity of R115,777 in the presence or absence
tamoxifen.
Effects of R115,777 and anti-estrogens on isoprenylated 
proteins
We have previously shown that AEBS is a multiprotein com-
plex consisting of enzymes involved in sterol biosynthesis [8],
suggesting that they possibly interfer with the mevalonate
pathway. For this reason we examined the capacity of Tam to
act on the protein farnesylation process. HDJ2 farnesylation, a
surrogate clinical marker for farnesyl transferase inhibitor activ-
ity, was used here as a reporter to define any potential inhibi-
tory effect on the mevalonate pathway. Fig. 5 shows western
blots of MCF-7 cells incubated with the three 'anti-estrogens'.
As a control, untreated cells exhibited complete prenylation of
HDJ2 (P, lane 1), while treatment with R115,777 (1 nM)
resulted in an accumulation of unprenylated HDJ2, seen as a
more slowly migrating band (U, lane 2). Furthermore, addition
of neither ICI182,780 (5 nM) nor Tam (5 µM) affected the far-
nesylation of HDJ2, either alone or in combination with
R115,777, which inhibits farnesylation of HDJ2 (lanes 3 to 6),
even though the HMG CoA reductase promoter has been
shown to be estrogen regulated [24]. The selective AEBS
ligand PBPE (10 µM), however, was able to regulate HDJ2 far-
nesylation itself in the absence of R115,777 (lane 7) and
further increased the effect of R115,777 (lane 8). Finally,
estradiol did not have any effect, either alone or in association
with R115,777, ICI182,780 or Tam (data not shown), or
indeed in the presence of PBPE (lane 9).
In this series of experiments, a low 1 nM concentration of
R115,777 was used so as to evaluate any increase of the
unfarnesylated protein resulting from exposure to the various
combinations. Among the three 'anti-estrogens' tested, it is
clear that PBPE interferes with the farnesylation of HDJ 2 (Fig.
5), as previously suggested in an earlier study with another
AEBS selective ligand in the farnesylation of H-ras [25]. Tam
exhibits only a slight or negligible effect on the same protein at
concentrations that cause apoptosis and growth inhibition of
MCF-7 cells; however, higher concentrations of Tam (50 µM)
that induce a high level of cell mortality are able to inhibit HDJ2
prenylation (data not shown). These observations therefore
suggest that, although Tam and PBPE bind AEBS with equiv-
alent affinity, they appear to have variable effects on the enzy-
matic activities of AEBS [5,20].
Any direct or indirect action of the AEBS ligands on the meval-
onate pathway were not examined in this study, but the fact
Figure 4
Effects of anti-estrogens and R115,777 on the caspase cleavage prod-uct of cytokeratin 18
uct of cytokeratin 18. Determined by FACS on MCF-7 cells incubated 
for 5 days with either 5 µM tamoxifen (Tx), 1 nM ICI182,780 (ICI) or 10 
µM N-pyrrolidine(-phenylmethyl-phenoxy)-ethanamine-HCl (PBPE) 
combined with 5, 10 or 25 nM R115,777. Floating and adherent cells 
were harvested, fixed and stained with the fluorescein conjugated mon-
oclonal antibody M30 CytoDeath and analysed using flow cytometry. 
Results are expressed as an index of specific fluorescence, as 
described in Materials and methods. Data are representative of one to 
three independent experiments in duplicate; variations were <1%.
Figure 5
Effects of anti-estrogens and R115,777 on isoprenylated proteins in MCF-7 cells
MCF-7 cells. Cells were incubated for 2 days with R115,777 (1 nM) 
combined with either tamoxifen (5 µM), ICI182777 (5 nM), N-pyrrolid-
ine(-phenylmethyl-phenoxy)-ethanamine-HCl (PBPE; 10 µM) or estra-
diol (1 nM). Floating and adherent cell lysates were resolved by SDS-
PAGE and blotted onto PVDF membranes and 5 µg protein were 
loaded for HDJ 2 detection, as described in Materials and methods. U, 
unprenylated; P, prenylated.
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biosynthesis [8], inducing the accumulation of different ster-
ols, could be a reason for the differences observed here in
their anti-farnesylation activities.
Conclusion
Although Tam is widely used for the treatment of ER positive
breast tumours, we have previously shown that the association
of Tam with FTI-277 led to an additive increase in its antipro-
liferative effects on MCF-7 cells [14]. Furthermore, other
authors have reported that hydroxy-tamoxifen (which binds
ERs in preference to AEBS) and also ICI182,780 (selective
for ER) act synergistically with FTI-277 in inhibiting the growth
of ER positive breast tumour cell lines [21]. As 4-hydroxyta-
moxifen and ICI182,780 have the same ER target, this study
was designed to determine which protein targets were
involved in the activity of Tam (the clinically used drug) in the
presence of a FTI. Bearing in mind that a combination of
R115,777 with Tam is already being evaluated in a clinical trial
[26,27], we have evaluated the effects of combining one of
three 'anti-estrogens' known to have different targets, Tam
(ERs and AEBS), ICI182,780 (selective for ERs) and PBPE
(selective AEBS ligand), with the FTI R115,777. Whereas
both ERs and AEBS appear to be involved in the antiprollifer-
ative effects seen with these combinations, the AEBS pathway
seems to be the main target involved in apoptosis induction.
Overall, this work reveals that combination of R115,777 with
either selective ER ligands or with the selective AEBS ligand
are able to induce large increases in their anti-proliferative
activities on MCF-7 cells. In view of these distinctive effects, it
might be informative to study combinations in different clinical
scenarios or employ them in sequence; studying the combina-
tion of an FTI with ICI182,780 for early treatment of ER posi-
tive breast tumours and reserving combinations with either
Tam or a selective AEBS ligand, such as the BMS-217380-01
[28], for more resistant disease.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
The authors' contributions to this work are reflected in the
order they are listed above, with the exception of JCF, who
supervised the research and the preparation of this report. FD,
CM, and MP carried out the experiments and FD drafted the
manuscript and performed the statistical analysis. MP pro-
vided PBPE and gave helpful advice on its mechanism of
action. GF gave helpful advice throughout this study. All
authors have read and approved the final manuscript.
Acknowledgements
This work was supported by INSERM, the French 'Ministère de l'Ensei-
gnement Supérieur et de la Recherche', Johnson and Johnson Pharma-
ceutical Research and Development, together with grants from the 
'Groupe de Recherche de l'Institut Claudius Regaud' and the 'Ligue 
Nationale de Lutte contre le Cancer'.
References
1. Baum C, Kirschmeier P: Preclinical and clinical evaluation of far-
nesyltransferase inhibitors.  Curr Oncol Rep 2003, 5:99-107.
2. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P,
Venet M, Sanz G, Poignet H, Skrzat S, et al.: Characterization of
the antitumour effects of the selective farnesyl protein trans-
ferase inhibitor R115777 in vivo and in vitro.  Cancer Res 2001,
61:131-137.
3. de Bono JS, Tolcher AW, Rowinsky EK: Farnesyltransferase
inhibitors and their potential in the treatment of breast
carcinoma.  Semin Oncol 2003, 30(5 Suppl 16):79-92.
4. Schiff R, Massarweh S, Shou J, Osborne CK: Breast cancer
endocrine resistance: how growth factor signaling and estro-
gen receptor coregulators modulate response.  Clin Cancer
Res 2003, 9:447S-454S.
5. De Medina P, Favre G, Poirot M: Multiple targeting by the antitu-
mour drug tamoxifen: a structure-activity study.  Curr Med
Chem Anti-Canc Agents 2004, 4:491-508.
6. Sutherland RL, Murphy LC, San Foo M, Green MD, Whybourne
AM, Krozowski ZS: High-affinity anti-oestrogen binding site
distinct from the oestrogen receptor.  Nature 1980,
288:273-275.
7. Faye JC, Jozan S, Redeuilh G, Baulieu EE, Bayard F: Physico-
chemical and genetic evidence for specific anti-estrogen bind-
ing sites.  Proc Natl Acad Sci USA 1983, 80:3158-3162.
8. Kedjouar B, De Medina P, Oulad-Abdelghani M, Payre B, Silvente-
Poirot S, Favre G, Faye JC, Poirot M: Molecular characterization
of the microsomal tamoxifen binding site.  J Biol Chem 2004,
279:34048-34061.
9. Sutherland RL, Hall RE, Taylor IW: Cell proliferation kinetics of
MCF-7 human mammary carcinoma cells in culture and effects
of tamoxifen on exponentially growing and plateau-phase
cells.  Cancer Res 1983, 43:3998-4006.
10. Delarue F, Kedjouar B, Mesange F, Bayard F, Faye JC, Poirot M:
Modifications of benzylphenoxy ethanamine anti-estrogen
molecules: influence affinity for anti-estrogen binding site
(AEBS) and cell cytotoxicity.  Biochem Pharmacol 1999,
57:657-661.
11. Mandlekar S, Yu R, Tan TH, Kong AN: Activation of caspase-3
and c-Jun NH2-terminal kinase-1 signaling pathways in
tamoxifen-induced apoptosis of human breast cancer cells.
Cancer Res 2000, 60:5995-6000.
12. Mandlekar S, Hebbar V, Christov K, Kong AN: Pharmacodynam-
ics of tamoxifen and its 4-hydroxy and N-desmethyl metabo-
lites: activation of caspases and induction of apoptosis in rat
mammary tumours and in human breast cancer cell lines.
Cancer Res 2000, 60:6601-6606.
13. Tamanoi F, Gau CL, Jiang C, Edamatsu H, Kato-Stankiewicz J:
Protein farnesylation in mammalian cells: effects of farnesyl-
transferase inhibitors on cancer cells.  Cell Mol Life Sci 2001,
58:1636-1649.
14. Doisneau-Sixou SF, Cestac P, Faye JC, Favre G, Sutherland RL:
Additive effects of tamoxifen and the farnesyl transferase
inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-
cycle progression.  Int J Cancer 2003, 106:789-798.
15. Doisneau-Sixou SF, Cestac P, Chouini S, Carroll JS, Hamilton AD,
Sebti SM, Poirot M, Balaguer P, Faye JC, Sutherland RL, et al.:
Contrasting effects of prenyltransferase inhibitors on estro-
gen-dependent cell cycle progression and estrogen receptor-
mediated transcriptional activity in MCF-7 cells.  Endocrinology
2003, 144:989-998.
16. Poirot M, De Medina P, Delarue F, Perie JJ, Klaebe A, Faye JC:
Synthesis, binding and structure-affinity studies of new lig-
ands for the microsomal anti-estrogen binding site (AEBS).
Bioorg Med Chem 2000, 8:2007-2016.
17. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D,
Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric
cytotoxicity assay for anticancer-drug screening.  J Natl Cancer
Inst 1990, 82:1107-1112.
18. Steel GG, Peckham MJ: Exploitable mechanisms in combined
radiotherapy-chemotherapy: the concept of additivity.  Int J
Radiat Oncol Biol Phys 1979, 5:85-91.
19. Brandes LJ: A diphenylmethane derivative selective for the
anti-estrogen binding site may help define its biological role.
Biochem Biophys Res Commun 1984, 124:244-249.
Available online http://breast-cancer-research.com/content/7/6/R1159
R116720. De Medina P, Payre BL, Bernad J, Bosser I, Pipy B, Silvente-Poirot
S, Favre G, Faye JC, Poirot ME: Tamoxifen is a potent inhibitor
of cholesterol esterification and prevent the formation of foam
cells.  J Pharmacol Exp Ther 2003.
21. Ellis CA, Vos MD, Wickline M, Riley C, Vallecorsa T, Telford WG,
Zujewskil J, Clark GJ: Tamoxifen and the farnesyl transferase
inhibitor FTI-277 synergize to inhibit growth in estrogen recep-
tor-positive breast tumour cell lines.  Breast Cancer Res Treat
2003, 78:59-67.
22. Bompard G, Puech C, Prebois C, Vignon F, Freiss G: Protein-
tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in
human breast cancer cells.  J Biol Chem 2002,
277:47861-47869.
23. Edamatsu H, Gau CL, Nemoto T, Guo L, Tamanoi F: Cdk inhibi-
tors, roscovitine and olomoucine, synergize with farnesyl-
transferase inhibitor (FTI) to induce efficient apoptosis of
human cancer cell lines.  Oncogene 2000, 19:3059-3068.
24. Di Croce L, Vicent GP, Pecci A, Bruscalupi G, Trentalance A,
Beato M: The promoter of the rat 3-hydroxy-3-methylglutaryl
coenzyme A reductase gene contains a tissue-specific estro-
gen-responsive region.  Mol Endocrinol 1999, 13:1225-1236.
25. Kedjouar B, De Medina P, Faye JC, Poirot M: Induction of apop-
tosis in human mammary carcinoma cells by (4-cumyl-phe-
noxy)-ethyl-N-pyrrolidine-HCl.  92nd Annual Meeting of the
Proceedings of the American Association for Cancer Research:
March 24–28 2001; New Orleans 2001.
26. Lebowitz PF, Eng-Wong J, Widemann BC, Balis FM, Jayaprakash
N, Chow C, Clark G, Gantz SB, Venzon D, Zujewski J: A phase I
trial and pharmacokinetic study of tipifarnib, a farnesyltrans-
ferase inhibitor, and tamoxifen in metastatic breast cancer.
Clin Cancer Res 2005, 11:1247-1252.
27. Head J, Johnston SR: New targets for therapy in breast cancer:
farnesyltransferase inhibitors.  Breast Cancer Res 2004,
6:262-268.
28. Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska
A, Gorbunova V, Garin A, Jassem J, et al.: Phase III study of N,N-
diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-
217380-01) combined with doxorubicin versus doxorubicin
alone in metastatic/recurrent breast cancer: National Cancer
Institute of Canada Clinical Trials Group Study MA.19.  J Clin
Oncol 2004, 22:269-276.
